

跨國藥廠賽諾菲宣布成立非營利事業部

誓言消除小兒麻痺、守護罕病病人

並為全球貧窮 40 個國家提供多元治療領域藥品

改寫、延長、到拯救生命 賽諾菲為貧窮國家帶來健康希望

(2021/04/16 台北訊)

「我們可以做更多！」賽諾菲為深化實踐企業社會責任，善用其在醫藥產業的領導地位，改變世界，賽諾菲執行長 Paul Hudson 正式宣布，將成立非營利事業部- 賽諾菲全球醫療志業(Sanofi Global Health)，對全球最貧窮的 40 個國家提供三十項必須藥品。並且每年資助千名罕病病人，以及投入兒童癌症、小兒麻痺、昏睡病之創新研究。賽諾菲全球醫療志業專注四大方向：提升藥品可近性，對弱勢族群的支持，環境保護，多元包容的工作環境，讓未來更健康美好。

Paul Hudson 表示，「這場全球的流行傳染病迫使我們重新思考生活中幾乎所有層面事物，包含生活方式和工作型態，以及我們如何與社區和地球共存。即便充滿挑戰，但對賽諾菲來說，這讓我們比任何其他時候都更接近我們的目標。面對危機與挑戰，更促使我們了對企業社會責任策略的抱負，希望以賽諾菲的使命與願景，幫助人們改變生活和實現更美好的未來。賽諾菲深信，我們可以做的更多。」

透過廣泛多元的藥品及全球布局優勢，賽諾菲全球醫療志業(Sanofi Global Health)，將專為全球 40 個最極端貧窮國家，提供高達 30 種涵蓋不同治療領域的藥品，包含心血管疾病、糖尿病、結核病、瘧疾和癌症，也同時為當地醫護提供培訓資源。此外，賽諾菲更承諾每年捐贈 10 萬瓶所需藥品給予 1000 名未獲治療的罕病病人，延續從過去 30 年以來賽諾菲為罕見疾病患者的不懈努力，為更多罕病生命點亮希望。



在中低收入國家，兒童死於小兒癌症的機率是高收入國家兒童的四倍。賽諾菲也將投入小兒癌症治療領域並研發創新藥品，降低兒童因癌症不幸被奪走生命的死亡率。尤其針對小兒麻痺以及昏睡病治療領域，賽諾菲訂立目標，將前與世界衛生組織共同努力，誓言在 2030 年前，消除這些容易被忽視，卻為全球 10 億多人口帶來痛苦與殘疾的疾病。過去 40 年來，賽諾菲已為全球供應數十億支小兒麻痺疫苗，包含已捐贈數億支疫苗來幫助全球全面消除小兒麻痺。

在環境保護方面，賽諾菲目標為在 2030 年前將溫室氣體排放量減少 55%。預計在 2025 年前使所有新產品均符合永續設計，在 2027 年全面替換疫苗的塑料包裝，以及 2030 年前，賽諾菲所有工廠將 **100%** 使用可再生電力，所有業務車隊均達到碳中和目標。身為跨國製藥公司，從領導團隊到員工，所有的工作都將以服務病患所需為中心。賽諾菲更致力使員工均享有公平機會擔任公司內所有職務，從而確保並促進整個公司的多元和包容。

關於賽諾菲

賽諾菲為專注於人類健康的全球生物製藥公司。我們透過治療藥物與疫苗，預防與治療疾病，並提供創新療法來緩解疼痛和減輕痛苦。我們支持迎戰罕見疾病的少數病友，以及數百萬罹患慢性疾病的病患。

賽諾菲集團遍布全球 100 個國家，並擁有超過 100,000 名員工，並將創新科學轉化為全球醫療保健解決方案。

前瞻性陳述 Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects” , “anticipates” , “believes” , “intends” , “estimates” , “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements